|
|
Post by peppy on Sept 7, 2017 13:46:01 GMT -5
Ok it does seem to be him... sorry for doubting. It mentions Mylan in this article. www.firstwordpharma.com/node/1503122?tsid=1Completely ignores his time at Mannkind. Ray was a Matt P hire so perhaps Mike has replaced him? I don't know but this is very bizarre. He was just on the Dash show right? I think it was aired a few weeks ago. watch it/him again.
www.youtube.com/watch?v=FrVkql2IYLw august 14, 2017 published.
|
|
|
|
Post by mango on Sept 7, 2017 13:47:18 GMT -5
|
|
|
|
Post by therealisaching on Sept 7, 2017 13:53:24 GMT -5
Well it makes way for a CMO hire from Amgen.
Kidding. Its too bad there is a disruption at this critical juncture.
|
|
|
|
Post by cjm18 on Sept 7, 2017 14:13:38 GMT -5
Ok so here are my thoughts: Ray was brought in from Mylan (producer of EpiPen) to spearhead EpiSphere development the leading technosphere candidate. As the company shifted it's attention and resources to Afrezza relaunch, Ray was left without the resources to start on the development and trials needed for this new application. Recently with the hiring of Locust Walk and Greenhill it likely became clear that the leading candidate for next technosphere application became Trep-T with Episphere is taking a back seat. It's possible Ray began searching for new opportunities at this point. Why did Mannkind not feel that this is material enough news to announce? I don't know. No PR because it looks bad to have an exec leave? |
|
|
|
Post by nylefty on Sept 7, 2017 14:34:21 GMT -5
Has the merger closed? If not, nothing is official. |
|
|
|
Post by mango on Sept 7, 2017 14:43:19 GMT -5
Has the merger closed? If not, nothing is official. It's expected to close before the end of the month. |
|
|
|
Post by peppy on Sept 7, 2017 14:52:59 GMT -5
Has the merger closed? If not, nothing is official. It's expected to close before the end of the month. same timing as the label change announcement. |
|
|
|
Post by radgray68 on Sept 7, 2017 14:58:48 GMT -5
What exactly is his work product? Aside from two years of some supposedly good pre-ind meetings with the FDA on Afrezza re-label, wait no it was palanosatron, wait trepostinil, wait epi-whatever, all endeavors that have provided NO fruit, what has he been doing?
I may have more faith in Urbansky if he had ever responded to my e-mails. Maybe It does take three years to advance a pipeline product one step, but the BP's seem to get it done a lot quicker, yes?
|
|
|
|
Post by sportsrancho on Sept 7, 2017 14:58:59 GMT -5
It's expected to close before the end of the month. same timing as the label change announcement. I'll bet we sell TS and Afrezza becomes a blockbuster. Women's gut instinct if Ray is gone... |
|
|
|
Post by therealisaching on Sept 7, 2017 15:02:41 GMT -5
Today's pr stated he started 9/1. The company's website is out of date at this point because it has a new name.
A side note on reverse splits since we all love them so much. This company announced a 300-1 RS. Stock was trading at $.06, then opened at $18 on 8/21. Looks like its going to close at $8 today. |
|
|
|
Post by babaoriley on Sept 7, 2017 15:15:28 GMT -5
Ok so here are my thoughts: Ray was brought in from Mylan (producer of EpiPen) to spearhead EpiSphere development the leading technosphere candidate. As the company shifted it's attention and resources to Afrezza relaunch, Ray was left without the resources to start on the development and trials needed for this new application. Recently with the hiring of Locust Walk and Greenhill it likely became clear that the leading candidate for next technosphere application became Trep-T with Episphere is taking a back seat. It's possible Ray began searching for new opportunities at this point. Why did Mannkind not feel that this is material enough news to announce? I don't know. My thought, a bit simpler: he pissed off Mike. |
|
|
|
Post by joeypotsandpans on Sept 7, 2017 15:17:39 GMT -5
Urbanksy was from the prior regime so it would not be a surprise if this is coming from Mike and he has another sharp replacement. The PR may be waiting for the replacement to officially leave a current position to be able to make an announcement. Obviously the price action really didn't flinch so looks like it's a non-issue and actually may be construed positively with any announcement.
|
|
|
|
Post by radgray68 on Sept 7, 2017 15:24:04 GMT -5
Ok so here are my thoughts: Ray was brought in from Mylan (producer of EpiPen) to spearhead EpiSphere development the leading technosphere candidate. As the company shifted it's attention and resources to Afrezza relaunch, Ray was left without the resources to start on the development and trials needed for this new application. Recently with the hiring of Locust Walk and Greenhill it likely became clear that the leading candidate for next technosphere application became Trep-T with Episphere is taking a back seat. It's possible Ray began searching for new opportunities at this point. Why did Mannkind not feel that this is material enough news to announce? I don't know. My thought, a bit simpler: he pissed off Mike. Yeah, Mike did say something about taking a step to advance the pipeline because of the extremely long road ahead. Perhaps there was some disagreement there. If we get a new and improved label, he's off my list. |
|
|
|
Post by madog365 on Sept 7, 2017 15:27:43 GMT -5
Ok so here are my thoughts: Ray was brought in from Mylan (producer of EpiPen) to spearhead EpiSphere development the leading technosphere candidate. As the company shifted it's attention and resources to Afrezza relaunch, Ray was left without the resources to start on the development and trials needed for this new application. Recently with the hiring of Locust Walk and Greenhill it likely became clear that the leading candidate for next technosphere application became Trep-T with Episphere is taking a back seat. It's possible Ray began searching for new opportunities at this point. Why did Mannkind not feel that this is material enough news to announce? I don't know. My thought, a bit simpler: he pissed off Mike. Maybe but since he had a new job already lined up on september 1st, to me that indicates he left of his own free will. If Mike had fired him, Mannkind would have planned to get a replacement before he was let go. My hope is that Locust Walk found someone to take on the costs of R+D for Mannkind, maybe it's a third party with a similar agreement as receptor or perhaps they are planning to bring in their own CMO. |
|
|
|
Post by peppy on Sept 7, 2017 15:39:18 GMT -5
same timing as the label change announcement. I'll bet we sell TS and Afrezza becomes a blockbuster. Women's gut instinct if Ray is gone... If your gut is correct, I would like to buy you and your gut a few drinks. |
|
